fimaVACC / PCI Biotech - LARVOL DELTA

Adjuvant-driven epitope hierarchy correlates with the protective efficacy of FimA vaccine against Klebsiella pneumoniae. (PubMed, Front Immunol) - "Immunization with a mixture of these FimA immunodominant epitopes plus AlPO4 achieved an 80% protection rate, where it exerted a potent therapeutic effect in combination with low-dose meropenem. Our findings revealed that adjuvants enhance anti-FimA immunity and modulate FimA epitope hierarchies across different vaccinated groups. Therefore, rational adjuvant selection may elicit effective FimA-induced responses in KP vaccines, wherein different FimA immunodominant epitopes induce protective humoral immune responses."

Journal • Infectious Disease • Pneumonia • Respiratory Diseases

HA2-FimA DNA Vaccine Treats Experimental Periodontitis. (PubMed, Oral Health Prev Dent) - "HA2-FimA DNA vaccine can increase the levels of SIgA and CAMP in the saliva of experimental periodontitis model rats and reduce alveolar bone loss."

Journal • Dental Disorders • Osteoporosis • Periodontitis

PCI Biotech interim Q4 2022 results (GlobeNewswire) - "FimaVacc – intratumoural immunotherapy - PCI Biotech is exploring approaches aimed at identifying novel immunotherapy treatment combination, and first patent application for an undisclosed treatment approach is underway for filing in Q1 2023."

Patent • Oncology